The Drug Administration of Vietnam, operating under the Ministry of Health, has issued an official regulatory directive addressed to provincial... Read more
Category: Uncategorized
Ministry of Health reviews expansion of health insurance coverage for traditional medicines to foster comprehensive care
The Ministry of Health has convened a national conference tasked with enhancing the quality and efficiency of Health Insurance (HI)... Read more
T-CURX acquires Pantherna Therapeutics to accelerate clinical validation of in-vivo CAR-T oncology therapies
German biotechnology developer T-CURX has entered into a definitive agreement to acquire its domestic peer, Pantherna Therapeutics, to systematically advance... Read more
Intravacc, Primrose Bio renew strategic alliance to advance conjugate vaccine development platforms
Global contract development and manufacturing organization (CDMO) Intravacc and biotechnology developer Primrose Bio have formalized a definitive renewal of their... Read more
US FDA approves Shionogi’s oral drug Xocova for post-exposure COVID-19 prevention
TOKYO (Reuters) — Japan's Shionogi & Co has announced that the U.S. Food and Drug Administration (FDA) has officially approved... Read more
CEPI commits over $60 million to Moderna and partners to accelerate Ebola vaccine development
The Coalition for Epidemic Preparedness Innovations (CEPI) has formalized a financial commitment of approximately $60 million distributed across Moderna and... Read more
Consolidation pact between Rallybio and Avenzo Therapeutics establishes updated equity distribution and clinical financing
Public equity markets logged a significant upward move for biotech developer Rallybio Corp., with its stock price hitting 24-month trading... Read more
Eli Lilly enters into $1.26 billion global licensing agreement with Hanmi Pharm for sonefpeglutide
U.S. pharmaceutical powerhouse Eli Lilly and Company and South Korea’s Hanmi Pharm have formalized a definitive licensing and commercialization agreement... Read more
Servier acquires Edgewise’s muscular dystrophy business for up to $2.65 billion to drive neurology expansion
U.S. biotech developer Edgewise Therapeutics has entered into a definitive agreement to sell its muscular dystrophy drug candidate and related... Read more









